Loading…
Danaher Corporation is projected to rise to $208.20 by 2027, a +20% move from its current price of $173.13. DHR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $170.95 | $173.21 | $175.50 | +0.05% |
| May 30 | $170.10 | $173.29 | $176.54 | +0.09% |
| May 31 | $169.47 | $173.37 | $177.36 | +0.14% |
| Jun 1 | $168.95 | $173.45 | $178.06 | +0.18% |
| Jun 2 | $168.50 | $173.52 | $178.70 | +0.23% |
| Jun 3 | $168.11 | $173.60 | $179.28 | +0.27% |
| Jun 4 | $167.75 | $173.68 | $179.82 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $167.75 | $173.68 | $179.82 | +0.32% |
| Week 2 | $165.88 | $174.24 | $183.01 | +0.64% |
| Week 3 | $164.58 | $174.79 | $185.64 | +0.96% |
| Week 4 | $163.57 | $175.35 | $187.97 | +1.28% |
| Week 5 | $162.75 | $175.91 | $190.12 | +1.60% |
| Week 6 | $162.07 | $176.47 | $192.15 | +1.93% |
| Week 7 | $161.48 | $177.03 | $194.08 | +2.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments.
The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish.
The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands.
The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984.
Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Danaher Corporation (DHR) is currently priced at $172.00 per share. It has a market capitalization of $121.74B and is ranked 127. The stock is categorized in Healthcare.
The current price sits near the middle of the 30-day range, with a neutral technical picture. RSI(14) is 40, and the stock trades below the 50-day simple moving average of $182.91 and the 200-day simple moving average of $206.57. The 30-day range runs from $156.93 to $188.52, with support at $161.91 and resistance at $198.61.
A major floor 18.3% below — a decisive break under it would weaken the trend.
The nearest floor, 6.5% below — buyers have tended to step in here.
The nearest ceiling, 14.4% above — a clean break opens room to run.
A major ceiling 39.8% above — clearing it would confirm fresh momentum.
Key DHR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DHR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $172.48 | Buy | $171.79 | Buy |
| MA 10 | $168.57 | Buy | $170.88 | Buy |
| MA 20 | $171.09 | Buy | $172.81 | Buy |
| MA 50 | $182.26 | Sell | $182.00 | Sell |
| MA 100 | $200.27 | Sell | $192.61 | Sell |
| MA 200 | $206.30 | Sell | $201.52 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.62 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 32.74 | Neutral |
| Williams %R (14) | -18.40 | Info |
| MACD (12,26,9) | 1.44 | Buy |
| ROC (12) | 1.15 | Buy |
| Bollinger %B (20,2) | 0.60 | Neutral |
| Stochastic %K (14) | 81.60 | Sell |
| TRIX (15) | -0.42 | Sell |
| Awesome (5,34) | -6.20 | Sell |
| Ultimate (7,14,28) | 69.71 | Neutral |
| Momentum (10) | 6.87 | Buy |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 174.91 | Sell |
| ADX (14) | 26.68 | Sell |
| ATR (14) | 2.04 | Info |
The 30-day technical picture shows a neutral stance. RSI(14) is 40, indicating neither overbought nor oversold conditions. The stock trades below the 50-day simple moving average of $182.91 and the 200-day simple moving average of $206.57.
Support is identified at $161.91 and resistance at $198.61, providing a defined trading set-up within the $156.93 to $188.52 range over the last 30 days.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $161.91 | $173.13 | $235.85 | 0% | Neutral | |
| $170.09 | $208.20 | $266.77 | +20% | Bullish | |
| $168.43 | $209.93 | $276.01 | +21% | Bullish | |
| $179.67 | $227.33 | $305.11 | +31% | Bullish | |
| $178.26 | $228.56 | $312.19 | +32% | Bullish | |
| $178.70 | $231.89 | $321.67 | +34% | Bullish | |
| $207.12 | $271.79 | $382.31 | +57% | Bullish | |
| $229.79 | $304.68 | $434.07 | +76% | Bullish | |
| $238.64 | $319.55 | $460.65 | +85% | Bullish | |
| $241.73 | $326.73 | $476.19 | +89% | Bullish | |
| $329.52 | $464.46 | $709.19 | +168% | Bullish | |
| $492.77 | $744.78 | $1,218.65 | +330% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $161.91 | $173.13 | $203.54 | +0.00% |
| June 2026 | $153.92 | $179.56 | $213.53 | +3.71% |
| July 2026 | $153.81 | $180.46 | $216.63 | +0.50% |
| August 2026 | $155.79 | $183.60 | $222.01 | +1.74% |
| September 2026 | $160.91 | $190.35 | $231.53 | +3.67% |
| October 2026 | $161.84 | $192.10 | $234.92 | +0.92% |
| November 2026 | $159.19 | $189.52 | $232.86 | -1.34% |
| December 2026 | $160.06 | $191.10 | $235.85 | +0.83% |
Click any year to see its month-by-month DHR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect DHR to range from $161.91 to $235.85 through 2026. The $173.13 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The DHR price prediction for 2027 points to an average of $208.20 (low $170.09, high $266.77) — a potential gain of +20% on today's $173.13. Momentum favours further upside here.
In 2028, DHR is projected to trade between $168.43 and $276.01, averaging $209.93 — a potential gain of +21% from today's $173.13. That is up +1% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Danaher Corporation's 2029 outlook centres on $227.33, within a $179.67 to $305.11 range. That is up +8% on the projected 2028 average. That marks a +31% change versus current levels. Momentum favours further upside here.
By 2030, DHR could reach as high as $312.19, with a base case around $228.56 and support toward $178.26 — roughly +32% from $173.13. Buyers look set to stay in control over this stretch.
Expect DHR to range from $178.70 to $321.67 through 2031. The $231.89 average target implies a +34% move from current prices. That is up +1% on the projected 2030 average. Momentum favours further upside here.
The DHR price prediction for 2032 points to an average of $271.79 (low $207.12, high $382.31) — a potential gain of +57% on today's $173.13. Buyers look set to stay in control over this stretch.
In 2033, DHR is projected to trade between $229.79 and $434.07, averaging $304.68 — a potential gain of +76% from today's $173.13. That is up +12% on the projected 2032 average. Momentum favours further upside here.
Danaher Corporation's 2034 outlook centres on $319.55, within a $238.64 to $460.65 range. That is up +5% on the projected 2033 average. That marks a +85% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, DHR could reach as high as $476.19, with a base case around $326.73 and support toward $241.73 — roughly +89% from $173.13. Momentum favours further upside here.
Expect DHR to range from $329.52 to $709.19 through 2040. The $464.46 average target implies a +168% move from current prices. That is up +42% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The DHR price prediction for 2050 points to an average of $744.78 (low $492.77, high $1,218.65) — a potential gain of +330% on today's $173.13. Momentum favours further upside here.
Investing $1,000 in DHR today (≈ 5.776006 DHR) could be worth
$4,301.83
+$3,301.83 (+330%) by 2050 · US Dollar
Based on the average projected DHR price of $744.78 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DHRwould be worth at today's price.
$1,000 invested in DHR on May 27, 2025 (≈ 5.285971 DHR) would be worth
$915.16
-$84.84 (-8.5%) today · 0.92× · US Dollar
Based on a DHR entry price of $189.18 vs. today's $173.13.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $171.12 | $1,011.75 | +1.2% |
| 1 month ago | $180.62 | $958.53 | -4.1% |
| 3 months ago | $209.36 | $826.95 | -17.3% |
| 6 months ago | $226.78 | $763.43 | -23.7% |
| 1 year ago | $189.18 | $915.16 | -8.5% |
| All time (5.0y) ago | $217.38 | $796.42 | -20.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DHR forecast.
Our base-case forecast reaches $350.00 around 2040.
Implied market cap at $350.00: $247.72B
The multi-year forecast shows a bullish trajectory after a flat 2026. The 2027–2031 period strengthens, with 2027 avg $207.03 and 2028 avg $208.75, leading into 2029 avg $227.18 and 2030 avg $227.31. The forecast for 2030–2035 remains bullish, with 2030 avg $227.31 and 2031 avg $230.80, and 2032–2035 showing continuous upside growth.
The 2030 forecast includes an average price of $227.31 with a max of $310.55 and a min of $177.26, delivering a 32.2% ROI. The 2040 forecast strengthens markedly, with an average price of $465.13, a max of $710.29, a min of $329.96, and a 170.4% ROI. By 2050, the average reaches $747.29 with a max of $1,222.87, a min of $494.39, and a 334.5% ROI.
These numbers imply a bullish long-run outlook with rising prices across the horizon, but they are estimates and not guarantees.
Tap a question to reveal the answer.
2030 avg $227.31; min $177.26; max $310.55; ROI 32.2%; sentiment BULLISH.
Forecasts show a bullish trajectory from 2027 onward, with rising average prices and positive ROI estimates (e.g., 2027 avg $207.03, ROI 20.4%; 2030 avg $227.31, ROI 32.2%; 2040 avg $465.13, ROI 170.4%; 2050 avg $747.29, ROI 334.5%). These are estimates, not guarantees.
Yes. The forecast for 2050 shows a max of $1,222.87, indicating the possibility of prices above $1,000 within the forecast horizon.
Current price is $172.00. Market cap is $121.74B, and the rank is 127.
The 30-day range is from $156.93 to $188.52, with support at $161.91 and resistance at $198.61.
Danaher Corporation Community Discussion
0Share your Danaher Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.